We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FUSB:NASDAQFirst US Bancshares, Inc. Analysis

Data as of 2026-06-11 - not real-time

$16.30

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

First US Bancshares (FUSB) is trading at $16.30, comfortably above its 20‑day ($16.05), 50‑day ($15.93) and 200‑day ($14.22) simple moving averages, signaling a sustained bullish trend. Technical indicators reinforce this view: the MACD histogram is positive (0.022) with a bullish crossover, and the RSI sits at a neutral 55.6, suggesting room for upside without immediate overbought pressure. Volume is increasing, and the price is holding above the identified support of $15.75 while approaching resistance near $16.45, indicating a potential short‑term consolidation point. Fundamentally, the stock trades at a PE of 15.7, modestly below the industry average of 16.5, and a price‑to‑book of 0.87, implying a discount to net asset value. The company boasts a solid balance sheet with $86.8 M in cash versus $12.6 M of debt (debt‑to‑equity effectively zero) and a modest ROE of 5.99%, complemented by a healthy operating margin of 25.1%. Dividend sustainability appears strong, with a 1.71% yield, a $0.07 per share payout, and a low payout ratio of 27%, reinforced by the recent cash dividend declaration. While the 30‑day volatility is elevated at ~21% and the beta is very low (0.27), the overall risk profile remains manageable, positioning FUSB as a potentially undervalued, dividend‑paying regional bank with upside potential.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near short‑term resistance at $16.45
  • Bullish technicals but limited upside in near term
  • Increasing volume supporting current price level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Valuation discounts (PE below industry, P/B < 1)
  • Strong balance sheet and low leverage
  • Sustainable dividend yield enhancing total return

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value suggests significant upside
  • Consistent earnings and operating margin stability
  • Low beta and defensive sector positioning

Key Metrics & Analysis

Financial Health

Revenue Growth6.00%
Profit Margin16.41%
P/E Ratio15.7
ROE5.99%
ROA0.54%
P/B Ratio0.9
Op. Cash Flow$14.7M
Industry P/E16.5

Technical Analysis

TrendBullish
RSI55.6
Support$15.75
Resistance$16.45
MA 20$16.05
MA 50$15.93
MA 200$14.22
MACDBullish
VolumeIncreasing
Fear & Greed Index84.61

Valuation

Fair Value$44.53
GradeUndervalued
TypeValue
Dividend Yield1.71%

Risk Assessment

Beta0.27
Volatility21.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.